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culated. Methods: The costs including lab investigation charges, unit costs of 
treatment per bed, medication charges, food costs, transportation costs and loss of 
productivity were calculated per asthma episode. Data was analysed by Statistical 
Package for the Social Sciences (SPSS) version 18.0 using various descriptive and 
inferential statistical tests. Results: A median medical cost of acute exacerbation 
of asthma under Ministry of Health’s (MOH) perspective was USD 105.00 (RM338.47) 
per episode. Medication cost comprised the majority (52.38%) of the total medical 
costs. A median medical cost of acute exacerbation of asthma under patient’s per-
spective was USD 1.55 (RM4.99) per episode. ConClusions: Asthma exacerbation 
and length of stay in the hospital were proportional to the direct medical costs. In 
Malaysia, a substantial proportion of the direct medical cost of asthma treatment 
is heavily subsidised for the locals.
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objeCtives: Acute exacerbation of chronic obstructive pulmonary disease 
(AECOPD) appears to be the main reason of hospitalization in COPD patients. Since 
substantial economic burden of COPD have not been previously studied in Malaysia, 
this study aimed at estimating and identifying different costs and related burden 
of illness in patients receiving treatment of AECOPD in a tertiary care hospital in 
Malaysia. Methods: A prospective follow-up study was performed in Department 
of Accident and Emergency and Respiratory Medicine of the hospital. Data were 
derived on the basis of per exacerbation episode. Relationship between direct medi-
cal costs and disease severity was analyzed using various descriptive and inferential 
statistical approaches. Results: Median actual direct medical costs and out-of-
pocket costs were RM 457.68 (US$ 141.97) and RM 28.25 (US$ 8.76) per exacerbation 
respectively. Drug cost (41%) was the leading cost driver, followed by unit cost of 
treatment per bed (33.6%) and lab investigation cost (25.4%). However, food cost 
(44.2%) represented the largest proportion in out-of-pocket costs. More than 90% of 
actual direct medical costs were supported by the Government of Malaysia in the 
patients studied. ConClusions: Impacts of AECOPD in health care resources are 
worthy of attention. Cost information from pharmacoeconomic studies is impor-
tant in decision making for health care professionals and policy makers in order to 
improve health care outcome and minimize costs.
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objeCtives: To conduct a study to determine the average cost of therapy for bron-
chial asthma patients in a tertiary care center. Methods: A prospective obser-
vational study was carried out on a 100 bronchial asthma patients after ethical 
clearance was obtained from an Independent Ethical Review (IEC) board. The patients 
selected for the study were in-patients admitted to the Medicine and Pulmonary 
wards for bronchial asthma related complaints with and without co-morbidities. 
The study assessed the average cost of therapy which was obtained from patient 
records. Statistical analysis was performed using SPSS version 20. Results: The 
mean age of the study population (N= 100) was 53.30±14.59. Females constituted 61% 
of the study population. The job profiles of the majority of study population were 
house wives (53%) and agriculturist (15%). The average cost of therapy among 100 
patients was found to range from $1.81 to $598. The impact on the length of stay on 
cost of therapy per day was classified into ≤ 5, 6-10, 11-21 days and cost was found to 
be $9.21 ± 5.57, $12.12 ±9.65 and $15.56±10.36 respectively. Impact of co-morbidities 
(35%) and without co-morbidities on cost of therapy per day was found to be $13.03 
± 10.63 and $8.54 ± 6.77 respectively. ConClusions: Asthma creates a substantial 
financial burden on the society and results in compromise on diagnosis and treat-
ment mainly in a developing country like India. There was a substantial increase in 
the cost of therapy as the duration of hospital stay increased and also in the case 
of patients with co-morbidities. Pharmacoeconomic analysis is needed to develop 
strategies to reduce the cost of therapy and thereby achieve greater medication 
adherence and improved quality of life in asthma patients.
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objeCtives: The objective of this cost study was to measure the resource utili-
sation and the direct costs associated with health care management of patients 
with chronic obstructive pulmonary disease (COPD) in Slovakia and to provide a 
basis for cost-effectiveness evaluations. Methods: The cross-sectional survey was 
performed to obtain the information on the management of patients with COPD 
and to estimate the direct costs of the disease management. The survey included 
4 experts experienced in COPD treatment. The studied population were cohorts of 
COPD patients evaluated separately according to the stage of the disease (mild, mod-
erate, severe and very severe). The patients were treated with standard therapy, the 
cost were set for one average patient per 3 months of treatment. The cost data were 
assessed and actualized due the 1st July 2014. All types of health care used in COPD 
management were evaluated (hospitalization, outpatient visits, diagnostics, labo-
ratory tests and the management of symptoms, use of bronchodilators). Moderate 
structure of direct costs in Russia was as follows – 77% for hospital stays, 21% for out-
patient visits, 2% for ambulance service. COPD exacerbations contributed the major 
portion of cost and also correlated with disease severity. ConClusions: COPD 
associated with significant economic burden on Russian’s health care system. There 
is a striking direct relationship between the cost of care and severity of the disease 
with hospitalization leading to disease exacerbation being a major portion of cost.
PRS34
the coStS of illneSS of atoPic deRmatitiS in South koRea
Kim C.M.1, Yim H.W.1, Jo S.J.1, Ahn S.H.1, Seo S.J.2, Choi W.S.1
1Catholic University College of Medicine, Seoul, South Korea,, 2Chung-Ang University, Seoul, South 
Korea
objeCtives: Atopic dermatitis is a global public health concern considering its 
growing prevalence and mounting socioeconomic burden. However, Few studies 
has assessed the economic impact of atopic dermatitis in Korea. To conduct a cost 
analysis of atopic dermatitis and evaluate the economic impact of the disease on 
individual annual disease burden, quality of life, and change in medical expenses 
in regards to change in health related quality of life. Methods: This prospective 
cost analysis of atopic dermatitis by reviewing the housekeeping account books 
of 32 patients was conducted and evaluated the economic impact of the disease 
by analyzing the completed questionnaires. To handle the potential uncertainties, 
we compared the results with the data released by the Health Insurance Review & 
Assessment Board on medical costs claimed by the health care facilities. Results: 
In regards to the cost of illness, direct cost of atopic dermatitis per patient during 
the 3 month study period was 541,280 KRW and expenditure on other atopic derma-
titis related products was 120,313 KRW. Extrapolated annual direct cost (including 
expenditures on other atopic dermatitis related product) per patient was 2,646,372 
KRW. Estimated annual indirect cost was 1,507,068 KRW. Annual cost of illness of 
atopic dermatitis, computed by adding up direct and indirect costs, was estimated 
to be 4,153,440 KRW. ConClusions: The annual total social cost on a national level 
was estimated at 5.8000 trillion KRW.
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objeCtives: There are three main funding sources of health system In Mongolia 
which are state budget, health insurance and out of pocket payment. Health insur-
ance funded health care service based on 115 DRG and total financing to health care 
organizations were 87.1 billion MNT in 2011. Health insurance rates 240000 MNT 
secondary and thirtary level of hospital by the same tariff. Aim of the study is to 
calculate 10 DRG costs which were spent 25 percent of the health insurance fund 
in 2012. Methods: We used both top down and bottom-up cost allocation method. 
Secondary data were used.  Results: Respiratory diseases finance is 9 percent 
higher than the real cost. Other 9 diagnostic groups finance were less than actual 
cost by 8-62%. That the total funding based on the number of cases nationwide, 
12,032,906,381 MNT funding was insufficient. ConClusions: Health insurance 
base tariff have to change based on the study while base rates should be different 
at secondary and thirtary level of health care organization.
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objeCtives: To assess the direct and indirect medical costs incurred in 
the treatment of tuberculosis (TB) in patients attending public hospitals in 
Pakistan. Methods: A descriptive cross-sectional study was conducted in patients 
attending Accident and Emergency and TB wards of the hospitals in Pakistan by con-
venient-sampling technique. The direct and indirect medical costs were determined 
by various parameters like consultation fees, cost of medicines, travelling costs 
and laboratory test expenses etc. All obtained data were analyzed using descrip-
tive and inferential statistics. Results: The mean annual direct medical cost for 
a TB patient was around Rs. 17317.56 (US$ 176.26) and indirect medical cost was 
Rs. 12918.50 (US$ 131.48). It was also observed that ccomparatively higher direct 
and indirect medical costs per patient (p < 0.001) were associated with large and 
urban hospitals. Besides, association of indirect medical costs with gender and age 
were the persuasive predictors of the study. ConClusions: Severity of the disease, 
distance to the hospital and length of stay in the hospital were proportional to the 
direct and indirect medical costs. In Pakistan, a significant proportion of the direct 
medical cost for TB treatment is subsidized for the public.
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objeCtives: The cost of acute exacerbations of asthma had not been well stud-
ied in literature. The aim of this study was to identify and quantify the (average) 
cost of moderate and severe exacerbations of asthma in patients attending ter-
tiary-care setup in Malaysia. The related burden of exacerbations was also cal-
